Recludix: targeting STATs via their SH2 domains

San Diego-based Recludix believes it has figured out how to effectively target the SH2 domains of STAT family signaling proteins to create therapies for inflammatory diseases and cancers with fewer side effects than JAK inhibitors. The company was founded in 2019, raised a $102 million series A, and partnered its STAT6 program with Sanofi last month. 

The JAK-STAT pathway plays well-established roles in inflammation and several JAK inhibitors are marketed for autoimmune diseases, but there’s room for improvement — in 2021, FDA required Eli Lilly and Co. (NYSE:LLY), AbbVie Inc. (NYSE:ABBV) and Pfizer Inc. (NYSE:PFE) to add warnings to the labels of their JAK inhibitors after Xeljanz tofacitinib showed an increased risk of serious heart-related conditions such as heart attacks and blood clots in a randomized safety clinical trial...